Recent Updates
Recently added Catalysts
RCEL Positive Sentiment Score: 75/100

AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Key Takeaway: AVITA Medical, Inc. (NASDAQ: RCEL) has announced that its CEO, Jim Corbett, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The company, which specializes in regenerative medicine, focuses on innovative devices for wound care management. The presentation can be attended live via an audio webcast, with a recording available post-event. AVITA's flagship product, the RECELL System, is designed to transform wound care and has multiple international approvals.

Market Sentiment Analysis

POSITIVE FACTORS

  • AVITA Medical is presenting at the prestigious J.P. Morgan Healthcare Conference.
  • The company is focused on innovative regenerative medicine technologies.
  • They have breakthrough products like the RECELL System that improve clinical outcomes.

Full Press Release Details

VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time.
A live audio webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at https://ir.avitamedical.com. A replay of the webcast will be available following the conclusion of the event.
About AVITA Medical, Inc.
AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding RECELL GO™, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Related Links

AVITA Medical Events & Presnetations
AVITA Medical Website

Contact Data

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.

Frequently Asked Questions

When will AVITA Medical present at the J.P. Morgan Healthcare Conference?

AVITA Medical will present on January 16, 2025, at 9:00 a.m. Pacific Time.

What is the RECELL® System used for?

The RECELL® System is used for treating thermal burns, skin defects, and vitiligo.

Where can I access the live webcast of AVITA's presentation?

The live webcast will be available on AVITA Medical's Events & Presentations webpage.

What technologies does AVITA Medical offer?

AVITA Medical offers the RECELL® System, PermeaDerm®, and Cohealyx™.

In which regions is the RECELL System approved?

The RECELL System is approved in the U.S., Australia, Europe, and Japan.

Last updated: Dec 18, 2024